Home » Topics » Regulatory

Regulatory
RSS

FDA approves two pain products from Mallinckrodt

Sep. 6, 1996

Serostim FDA-approved for cachexia in AIDS patients

Aug. 30, 1996

Expanded H-BIG clinical development program announced

Aug. 30, 1996

FDA approves Helidac for marketing

Aug. 30, 1996

Botulinum toxin effective in treating writer's cramp

Aug. 30, 1996

Botulinum toxin effective in reducing upper limb spasticity

Aug. 30, 1996

Tegretol-XR launched in U.S.

Aug. 30, 1996

Famotidine tested in schizophrenic patients

Aug. 30, 1996

BMS, Sano to collaborate on transdermal BuSpar development

Aug. 30, 1996

Flunitrazepam may alter circadian sleep-wake rhythms

Aug. 30, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 11, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 11, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.